Specific correlates of CAA (white matter microstructure and cortical atrophy adjusted for APOE ε4 carriership) and arteriolosclerosis (white matter lesion and hippocampal atrophy adjusted for hypertension) could be potential candidates for screening of individuals at risk for developing ARIA, thereby improving future clinical trial design. This evidence concerns the gene APOE and Cerebral cortical atrophy.